Novo-Nordisk A/S has acquired the licensing of a new weight loss drug from a Guangdong pharmaceutical factory, targeting the strength of Innovative Drugs in China.

① Due to the next-generation weight loss drug CagriSema's experimental data failing to convince the market, Novo-Nordisk A/S's stock price has halved in the past year; ② Novo-Nordisk A/S announced on Monday a deal to acquire the overseas rights to China's Innovative Drugs UBT251 for up to 2 billion USD; ③ Analysts expect UBT251 to show data comparable to Eli Lilly and Co's next-generation weight loss drug Retatrutide.

cls.cn19:23 ET

Top Gap Ups and Downs on Monday: BUD, GSK, MFG and More

Moomoo News18:00 ET · Markets

U.S. stocks closed: Trump signals tariff exemptions and the three major U.S. stock indices all rose.

1. Trump's latest statement alleviates anxiety over tariff impacts, with all three major indexes rising, the Nasdaq up over 2%, and Tesla nearly rising 12%; 2. Targeting China's Innovative Drugs capabilities, Novo-Nordisk A/S acquires authorization for a new weight loss drug from a Guangdong pharmaceutical factory; 3. The "Priority Notification" feature appears in Apple's iOS 18.4 RC version; 4. Alibaba open-sources the Qwen2.5-VL-32B-Instruct model.

cls.cn17:27 ET

Sector Update: Health Care Stocks Higher in Afternoon Trading

MT Newswires13:54 ET

Germany's SAP Overtakes Wegovy Maker Novo Nordisk as Europe's Most Valuable Company -- 2nd Update

WSJ13:16 ET

Novo Nordisk Down 15% in March: Is This a Buying Opportunity?

Zacks Mar 24 10:45 ET